The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were ...

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

THOUSAND OAKS, California-The US Food and Drug Administration has approved Amgen’s Aranesp (darbepoetin alfa) for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies.

April 6, 2005 — The U.S. Food and Drug Administration (FDA) announced in January revisions to safety labeling to advise healthcare professionals of the following changes: use of darbepoetin alfa ...

A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...

The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia.

Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase ...

The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ...